1 |
Holman A, Parikh N, Clauw DJ, Williams DA, Tapper EB. Contemporary management of pain in cirrhosis: Toward precision therapy for pain. Hepatology 2023;77:290-304. [PMID: 35665522 DOI: 10.1002/hep.32598] [Reference Citation Analysis]
|
2 |
Liu Y, Wu Q, Sun T, Huang J, Han G, Han H. DNAAF5 promotes hepatocellular carcinoma malignant progression by recruiting USP39 to improve PFKL protein stability. Front Oncol 2022;12:1032579. [DOI: 10.3389/fonc.2022.1032579] [Reference Citation Analysis]
|
3 |
Allaire M, Bruix J, Korenjak M, Manes S, Maravic Z, Reeves H, Salem R, Sangro B, Sherman M. What to do about Hepatocellular Carcinoma: Recommendations for Health Authorities: An International Liver Cancer Association Advocacy Document. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100578] [Reference Citation Analysis]
|
4 |
Kardashian A, Serper M, Terrault N, Nephew LD. Health disparities in chronic liver disease. Hepatology 2022. [PMID: 35993341 DOI: 10.1002/hep.32743] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
5 |
Zhou Y, Qiu J, Liu S, Wang P, Ma D, Zhang G, Cao Y, Hu L, Wang Z, Wu J, Jiang C. CFDP1 promotes hepatocellular carcinoma progression through activating NEDD4/PTEN/PI3K/AKT signaling pathway. Cancer Med 2023;12:425-44. [PMID: 35861040 DOI: 10.1002/cam4.4919] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
6 |
Chen T, Tam N, Mao Y, Sun C, Wang Z, Hou Y, Xia W, Yu J, Wu L. A multi-hit therapeutic nanoplatform for hepatocellular carcinoma: Dual stimuli-responsive drug release, dual-modal imaging, and in situ oxygen supply to enhance synergistic therapy. Materials Today Bio 2022. [DOI: 10.1016/j.mtbio.2022.100338] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|